Fundraisings and IPOs

Date: 2017-11-29

Type of information: Private placement

Company: Y-mAbs Therapeutics (US - NY)

Investors: HBM Healthcare Investments (Switzerland), current shareholders, Sofimac Partners (France) Scopia Capital Management (US - NY)

Amount: $80 million

Funding type: private placement

Planned used:

  • The proceeds of the financing will be used to advance the development of YmAbs portfolio of late-stage oncology compounds including burtomab and naxitamab, establish sales and marketing capabilities, and bolster general working capital.
  • The financing will strengthen Y-mAbs Therapeutics’ balance sheet and position it for continued progress as it initiates and completes additional clinical trials targeting a variety of cancers.


  • • On November 29, 2017, Y-mAbs Therapeutics announced that it has completed an extended closing of an additional $30 million in a private equity placement, adding institutional investors Sofinnova Ventures and Scopia Capital Management to its list of shareholders. Together, with the $50 million raised in the first closing, Y-mAbs  has now raised $80 million pursuant to this private placement round. • On October 24, 2017, Y-mAbs Therapeutics announced that it has closed a private placement among HBM Healthcare Investments and its current shareholders raising $50 million.

Therapeutic area: Cancer - Oncology

Is general: Yes